{"slideshow_credits": null, "snippet": "The drug inhibits the protein PCSK9 and might one day be used to treat millions of people whose cholesterol is not lowered enough by common statins, such as Lipitor.", "abstract": "Medicines Company will license the rights to powerful cholesterol-lowering drug ALN-PCS from Alnylam Pharmaceuticals, entering one of hottest races in industry.", "section_name": "Business Day", "print_page": "5", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/02/04/business/medicines-co-licenses-rights-to-cholesterol-drug.html", "lead_paragraph": "The drug inhibits the protein PCSK9 and might one day be used to treat millions of people whose cholesterol is not lowered enough by common statins, such as Lipitor.", "headline": {"seo": "Medicines Co. Licenses Rights to Cholesterol Drug", "main": "Medicines Co. Buys Cholesterol Drug Rights", "print_headline": "Medicines Co. Buys Cholesterol Drug Rights"}, "_id": "510f44bf00315214fbb88f54", "word_count": "396", "multimedia": [], "pub_date": "2013-02-04T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Cholesterol", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Statins (Cholesterol-Lowering Drugs)", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Medicines Company", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Roche Holding A G", "name": "organizations", "is_major": "N", "rank": "5"}, {"value": "Alnylam Pharmaceuticals Inc", "name": "organizations", "is_major": "Y", "rank": "6"}, {"value": "Cambridge (Mass)", "name": "glocations", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "News"}